Critical Contrast: Sharps Technology (NASDAQ:STSS) & Delcath Systems (NASDAQ:DCTH)

Delcath Systems (NASDAQ:DCTH) and Sharps Technology (NASDAQ:STSS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Institutional & Insider Ownership

61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 17.2% of Sharps Technology shares are owned by institutional investors. 21.1% of Delcath Systems shares are owned by insiders. Comparatively, 14.1% of Sharps Technology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Delcath Systems and Sharps Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Delcath Systems	-2,308.86%	-563.60%	-111.13%
Sharps Technology	N/A	-103.10%	-76.46%

Analyst Ratings

This is a summary of current recommendations for Delcath Systems and Sharps Technology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	0	0	4	0	3.00
Sharps Technology	0	0	1	0	3.00

Delcath Systems currently has a consensus target price of $18.50, suggesting a potential upside of 279.88%. Given Delcath Systems’ higher possible upside, research analysts clearly believe Delcath Systems is more favorable than Sharps Technology.

Volatility & Risk

Delcath Systems has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Sharps Technology has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.

Earnings and Valuation

This table compares Delcath Systems and Sharps Technology’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$2.07 million	57.78	-$47.68 million	($2.97)	-1.64
Sharps Technology	N/A	N/A	-$9.84 million	N/A	N/A

Sharps Technology has lower revenue, but higher earnings than Delcath Systems.

About Delcath Systems

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

About Sharps Technology

Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.